Visiopharm is pleased to announce the novel deployment of Visiopharm’s existing diagnostic decision support APPs (CE under IVDR) for University Medical Centre Utrecht (UMC Utrecht) in the Netherlands. Those include applications for ER, PR, HER2 and Ki-67 biomarker quantification as well as a deep-learning based lymph node metastasis detection algorithm (H&E). Visiopharm will also install newly acquired Hamamatsu scanners at UMC Utrecht.
On the research side, Visiopharm will furthermore launch its automated AI-driven digital pathology workflow at UMC Utrecht, which is currently for research only and not for diagnostic purposes. It includes fully automated (zero-click) deep-learning based APPs, that are automating essential steps in the workflow: Automated detection of patient tissue (versus control tissue); automated quality control (identifying missing tumor, necrosis, folds, tears, out-of-focus areas, pen marks, and debris for example); detection of invasive/pre-invasive tumor versus stroma; handling tumor heterogeneity; and identification and quantification of microstructural content including biomarker expression. By doing so, the analysis results will be ready for the pathologist at time of case review. Once the validation phase is finalized, Visiopharm will apply for CE-IVD certification for those new deep-learning-based APPs.
Prof Paul van Diest, UMC Utrecht, said:
“Visiopharm is a very dedicated AI company that has taken precision pathology to the level of daily practice including full IVDR compliance, which we regard as a necessary requirement for a future-proof patient-safe system. There is a very strong alignment with our vision for AI-driven workflows and transformation, from fully glass-based pathology to fully-digital AI supported pathology.”
Martin Kristensson, SVP Global Clinical Sales, Visiopharm said:
“UMC Utrecht and Prof Paul Van Diest are true trailblazers in this field, creating a blueprint for others to follow when undertaking the full digital transformation of a pathology lab. We are very excited to support UMC Utrecht in achieving their vision of delivering precision pathology to their care centers and for their patients, using the best scanning technology from Hamamatsu, and AI-enhanced digital pathology workflows. Our ultimate goal is to support UMC Utrecht in realizing improved patient outcomes, as well as cost and time-savings, through automation, quality control, and increased precision.”
Dirk Vossen, Chief Diagnostic Officer, Visiopharm said:
“We only see the launch of Oncotopix® with our IVDR-compliant APPs as the beginning of an exciting collaboration, where our combined decades-long experience in digital pathology and best practices on AI-based image analysis will raise the bar for standardization and automation – the two key ingredients in sustainable cancer healthcare. We have already agreed to give UMC Utrecht access to our novel products, including Qualitopix™, to further develop and validate our joint vision for AI-driven precision pathology.”
Visiopharm® is a world leader in AI-driven precision pathology software. Their pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs provide decision support. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2002 and is privately owned. The company operates internationally with over 750 customer accounts and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, The Netherlands and United States.